Tynor Orthotics, supported by a recent $200 million investment from Kedaara Capital, has set ambitious goals to dominate the Indian market and significantly boost its revenue. The company aims to increase its domestic market share from approximately 29% to over 50% by fiscal year 2031, projecting a nearly threefold rise in revenue to Rs 1,767 crore.
Strategic Expansion and New Product Verticals
An internal valuation report, reviewed by Business Today, outlines the key pillars of Tynor's growth strategy. A significant shift involves moving away from a predominantly prescription and pharmacy-led model to an omnichannel, over-the-counter (OTC) driven approach, supported by targeted digital consumer campaigns.
The company plans to expand beyond its core orthotics business into new product categories. This includes launching three new sub-brands catering to compression, mobility, wellness, sports, and lifestyle products, diversifying its offering to a broader consumer base.
Financial Projections and Investment in Growth
Tynor's financial projections indicate robust growth, with revenue from operations expected to climb from Rs 582.9 crore in FY26 to Rs 1,767.3 crore in FY31, representing a compound annual growth rate (CAGR) of 24.8%. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is also projected to rise from Rs 161.9 crore in FY27 to Rs 427.3 crore in FY31, with margins improving due to backward integration and operational efficiencies.
To support this aggressive expansion, Tynor is allocating approximately Rs 222 crore in growth capital expenditure over the next five years, with significant investments planned for FY27 and subsequent years.
Global Aspirations and Operational Enhancements
Beyond India, Tynor intends to replicate its successful business model across emerging economies. Simultaneously, the company plans to forge CDMO (Contract Development and Manufacturing Organization) and OEM (Original Equipment Manufacturer) partnerships with established orthopedic brands and retail chains in developed markets. Eventually, Tynor aims to enter prescription and insurance-driven segments under its own brand internationally.
Operational improvements, including progressive backward integration into manufacturing key inputs, are expected to further enhance profitability and support the company's long-term growth trajectory. Kedaara Capital and Tynor's promoters, Dr. P.J. Singh and A.J. Singh, expressed confidence in the partnership to transform Tynor into a global orthotics champion and an indispensable supply chain partner.